Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics

被引:120
作者
Rengelshausen, J
Banfield, M
Riedel, KD
Burhenne, J
Weiss, J
Thomsen, T
Walter-Sack, I
Haefeli, WE
Mikus, G
机构
[1] Heidelberg Univ, Dept Internal Med 4, D-69120 Heidelberg, Germany
[2] Pharm PlanNet, Monchengladbach, Germany
关键词
D O I
10.1016/j.clpt.2005.01.024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: Constituents of St John's wort (SJW) in vivo induce the cytochrome P450 (CYP) isozymes 3A4, 2C9, and 2C19 but in vitro were shown to inhibit them. This study investigates both short- and long-term effects of SJW on the antifungal voriconazole, which is metabolized by these enzymes. Methods. In a controlled, open-label study, single oral doses of 400 mg voriconazole were administered to 16 healthy men stratified for CYP2C19 genotype before and on day 1 and day 15 of concomitant SJW intake (300 mg LI 160 3 times daily). Plasma and urine concentrations of voriconazole were determined by liquid chromatography with mass-spectrometric detection. Results: During the initial 10 hours of the first day of SJW administration, the area under the voriconazole plasma concentration-time curve was increased by 22% compared with control (15.5 +/- 6.84 h center dot mu g/mL versus 12.7 +/- 4.16 h center dot mu g/mL, P = .02). After 15 days of SJW intake, the area under the plasma concentration-time curve from hour 0 to infinity was reduced by 59% compared with control (9.63 +/- 6.03 h center dot mu g/mL versus 23.5 +/- 15.6 h center dot mu g/mL, P = .0004), with a corresponding increase in oral voriconazole clearance (CL/F) from 390 +/- 192 to 952 +/- 524 mL/min (P = .0004). The baseline CL/F of voriconazole and the absolute increase in CL/F were smaller in carriers of I or 2 deficient CYP2C19*2 alleles compared with wild-type individuals (P < .03). Conclusions. Coadministration of SJW leads to a short-term but clinically irrelevant increase followed by a prolonged extensive reduction in voriconazole exposure. SJW might put CYP2C19 wild-type individuals at highest risk for potential voriconazole treatment failure.
引用
收藏
页码:25 / 33
页数:9
相关论文
共 40 条
[1]   Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients [J].
Bauer, S ;
Störmer, E ;
Johne, A ;
Krüger, H ;
Budde, K ;
Neumayer, HH ;
Roots, I ;
Mai, I .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (02) :203-211
[2]   Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter [J].
Chen, YP ;
Ferguson, SS ;
Negishi, M ;
Goldstein, JA .
MOLECULAR PHARMACOLOGY, 2003, 64 (02) :316-324
[3]   Drug therapy - Herbal remedies. [J].
De Smet, PAGM .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) :2046-2056
[4]   Clinical significance of the cytochrome P4502C19 genetic polymorphism [J].
Desta, Z ;
Zhao, XJ ;
Shin, JG ;
Flockhart, DA .
CLINICAL PHARMACOKINETICS, 2002, 41 (12) :913-958
[5]   Coordinate induction of both cytochrome P4503A and MDRI by St John's wort in healthy subjects [J].
Dresser, GK ;
Schwarz, UI ;
Wilkinson, GR ;
Kim, RB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (01) :41-50
[6]   St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 [J].
Dürr, D ;
Stieger, B ;
Kullak-Ublick, GA ;
Rentsch, KM ;
Steinert, HC ;
Meier, PJ ;
Fattinger, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (06) :598-604
[7]   Rifampin and Rifabutin drug interactions - An update [J].
Finch, CK ;
Chrisman, CR ;
Baciewicz, AM ;
Self, TH .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (09) :985-992
[8]   Effect of St John's wort on imatinib mesylate pharmacokinetics [J].
Frye, RF ;
Fitzgerald, SM ;
Lagattuta, TF ;
Hruska, MW ;
Egorin, MJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (04) :323-329
[9]   Effects of St. John's Wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers [J].
Hebert, ME ;
Park, JM ;
Chen, YL ;
Akhtar, S ;
Larson, AM .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (01) :89-94
[10]   St John's wort (Hypericum perforatum):: drug interactions and clinical outcomes [J].
Henderson, L ;
Yue, QY ;
Bergquist, C ;
Gerden, B ;
Arlett, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (04) :349-356